Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus BENADRYL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus BENADRYL PRESERVATIVE FREE.
ALLEGRA HIVES vs BENADRYL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Category C
Category C
Antihistamine
Antihistamine